Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 23;15(1):101.
doi: 10.1038/s41408-025-01304-x.

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia

Affiliations

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia

Mélinda Dantec et al. Blood Cancer J. .

Abstract

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the Lille University Hospital Institutional Review Board (Number CSTMT028). All participants provided written informed consent prior to inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki.

Figures

Fig. 1
Fig. 1. IDH1/2-mutated AMLs from the French HDF-AML observatory.
A General flowchart of the study. B Distribution of IDH1/2 mutations. Apart from 2 patients, mutational hotspots were mutually exclusive. C Localization of IDH1/2 mutations. A total of 89 IDH1 mutations and 120 IDH2 mutations (VAF ≥ 10%) from 206 AML patients were identified. One patient had two distinct IDH1 mutations (R132G/R132C) and two patients had mutations in both IDH1 and IDH2 (R132C/R140Q, R132S/R140W). The proportion of NPM1 co-mutations is indicated for each codon. D WBC count according to IDH mutation codon. E Molecular landscape and cytogenetics of IDH1/2-mutated AMLs.
Fig. 2
Fig. 2. Prognostic determinants of IDH1/IDH2-mutated AML patients treated with ICT.
Overall survival according to A the IDH-mutated codon, B age group, C ELN 2022 risk stratification, D combined NPM1 and DNMT3A status, E IDH1/2 mutation persistence (≥0.1%) at post-course 1 (PC1), F IDH1/2 mutation persistence at post-course 2 (PC2), G IDH1/2 mutation persistence before transplant, and H IDH1/2 mutation persistence at day 100 after transplant.

Similar articles

References

    1. DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90:732–6. - PMC - PubMed
    1. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010;116:2779–82. - PubMed
    1. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118:409–12. - PubMed
    1. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89. - PMC - PubMed
    1. Shen Y, Zhu Y-M, Fan X, Shi J-Y, Wang Q-R, Yan X-J, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118:5593–603. - PubMed

LinkOut - more resources